AI Science Tracker

BindCraft designs protein binders in one shot

EPFL; Swiss Institute of Bioinformatics · 27 Aug 2025 · biology

Discovery

BindCraft designs protein binders in one shot

An open AlphaFold2-based hallucination pipeline designs binders with reported experimental success rates of 10-100% across 12 targets, with affinities predominantly in the nanomolar range. The authors also demonstrated effects in cell assays and patient-derived samples; these are experimental results, not established clinical treatments. This entry uses the Nature publication date (27 August 2025); the preprint appeared in 2024.

Technology: BindCraft (AlphaFold2-based design)

Family AlphaFold: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Binders tested experimentally across 12 targets (receptors, allergens, de novo proteins, nucleases) with reported success rates of 10-100%, plus functional assays in patient-derived samples and cell assays.
  • Still unknown: The abstract gives no number of designs per target or per-target success rates, and states no limitations.
  • AI role: Open-source automated pipeline using AlphaFold2 weights to design binders in one shot, without high-throughput screening.

Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-025-09429-6&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 454 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.